Compare UTHR & J Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTHR | J |
|---|---|---|
| Founded | 1996 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.4B | 17.5B |
| IPO Year | 1999 | 1994 |
| Metric | UTHR | J |
|---|---|---|
| Price | $500.47 | $138.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 10 |
| Target Price | ★ $520.00 | $156.60 |
| AVG Volume (30 Days) | 307.6K | ★ 1.1M |
| Earning Date | 05-28-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 1.03% |
| EPS Growth | ★ 13.07 | N/A |
| EPS | ★ 27.86 | 1.12 |
| Revenue | $1,483,300,000.00 | ★ $14,984,646,000.00 |
| Revenue This Year | $8.56 | N/A |
| Revenue Next Year | $10.71 | $6.44 |
| P/E Ratio | ★ $18.21 | $124.52 |
| Revenue Growth | 2.38 | ★ 49.51 |
| 52 Week Low | $266.98 | $106.23 |
| 52 Week High | $537.19 | $168.44 |
| Indicator | UTHR | J |
|---|---|---|
| Relative Strength Index (RSI) | 56.75 | 49.85 |
| Support Level | $463.06 | $127.79 |
| Resistance Level | $516.36 | $141.60 |
| Average True Range (ATR) | 17.02 | 5.91 |
| MACD | 3.90 | -0.32 |
| Stochastic Oscillator | 50.18 | 44.73 |
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Jacobs Solutions is a global provider of engineering, design, procurement, construction, and maintenance services as well as cyber engineering and security solutions. The firm serves industrial, commercial, and government clients in a wide variety of sectors, including water, transportation, healthcare, technology, and chemicals. Jacobs Solutions employs approximately 60,000 workers. The company generated $12 billion in revenue in fiscal 2025.